12,372 trials
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.42; -0.82; -0.97 % of hemoglobin — p=0.0007
Crohn's Disease · Colitis · IBD
Primary: Number of Participants With Clinical Remission at Week 44 — 47; 63; 68 participants — p=0.040
Breast Cancer
Primary: Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment — 63.3; 64.3; 59.8 percentage of participants
Soft Tissue Surgical Bleeding
Primary: Percentage of Subjects Achieving Hemostasis Within 4 Minutes After Treatment Start — 82.8; 77.8 percentage of participants
Infections, Rotavirus
Primary: Number of Seroconverted Subjects Against Human Rotavirus — 363; 319 Subjects
Schizophrenia
Primary: Safety and Tolerability — 337 TEAEs
Diabetic Macular Edema
Primary: The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months — 0; 0.53 ETDRS letters
Hepatitis A
Primary: Number of Seropositive Subjects for Anti-HAV Antibodies — 106; 94 Participants
Non Functioning Entero-pancreatic Endocrine Tumour
Primary: Adverse Events — 40; 46; 86 participants with any TEAEs
Colitis, Ulcerative
Primary: Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score — 6; 18 participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.45; -0.46 percentage of glycosylated haemoglobin — p=< 0.001
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
Hepatitis C
Primary: Percentage of Participants Maintaining SVR at the Last Available Visit — 100 Percentage of participants
Meningococcal Disease
Primary: Percentages of Subjects With Serum Bactericidal Activity Using Human Complement (hSBA) Titers ≥ 5 for B Indicator Strains (H44/76, 5/99, and NZ98/254) and M10713 Strain…
Hemophilia B
Primary: Intraoperative Hemostatic Efficacy — 37; 20; 17; 1 surgeries